Monopar Therapeutics Inc. Accretion (Amortization) of Discounts and Premiums, Investments
Monopar Therapeutics Inc. (MNPR) reported Accretion (Amortization) of Discounts and Premiums, Investments of $1.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments · last filed 2026-08-12
- Monopar Therapeutics Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-06-30 was $708.01K, a 649.08% increase year-over-year.
- Monopar Therapeutics Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-03-31 was $799.63K, a 569.10% increase year-over-year.
- Monopar Therapeutics Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-06-30 was $94.52K.
- Monopar Therapeutics Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-03-31 was $119.51K.
- Monopar Therapeutics Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2025 was $716.46K, a 7846.58% increase from fiscal 2024.
- Monopar Therapeutics Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2024 was $9.02K.
| Period end | Accretion (Amortization) of Discounts and Premiums, Investments 3 month | Accretion (Amortization) of Discounts and Premiums, Investments 6 month | Accretion (Amortization) of Discounts and Premiums, Investments 12 month |
|---|---|---|---|
| 2026-06-30 | $708.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.51M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $799.63K 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $716.46K 10-K · filed 2026-03-27 | ||
| 2025-06-30 | $94.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $214.03K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $119.51K 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $9.02K 10-K · filed 2026-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |